- Trial phase
- Approved
- Time to market
- Already approved and marketed. First FDA approval was November 2024 (BTC), second was August 2026 (GEA).
- Why 4/10
- Ziihera is already FDA-approved in two indications (BTC in Nov 2024, GEA in Aug 2026) with no pending regulatory decision or hard dated binary catalyst in the next ~12 months. The next potential catalyst would be a regulatory filing for HER2+ colorectal cancer following the Aug 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. As an approved, commercial-stage drug, the defining binary catalysts have passed.
Ziihera is already approved in two indications (BTC and GEA) and generating royalty revenue through partners Jazz and BeOne. The next major catalyst would be a potential regulatory filing for HER2+ colorectal cancer following the August 2026 Breakthrough Therapy Designation, but no PDUFA date has been set. Watch for quarterly royalty revenue growth and any label expansion filings as the key value drivers.
Price Chart
Executive Summary
Ziihera (zanidatamab) is a HER2-targeted bispecific antibody developed by Zymeworks Inc. (Nasdaq: ZYME) and commercialized by partners Jazz Pharmaceuticals and BeOne Medicines. It has received two FDA approvals: first in November 2024 for previously treated HER2-positive biliary tract cancer, and second in August 2026 for first-line HER2-positive advanced gastroesophageal adenocarcinoma (GEA), where Phase 3 data showed statistically significant overall survival improvement over the standard-of-care trastuzumab. Zymeworks has pivoted to a royalty-driven business model, collecting milestones and royalties from its partners, and raised 2026 revenue guidance to $337M-$351M after reporting Q3 revenue of $256.5M. The stock trades near its 52-week high with a Strong Buy analyst consensus and a mean price target of $41.50, implying ~40% upside.
How It Works
Ziihera is a bispecific antibody, meaning it is an engineered protein that can grab onto two different spots at once. It targets the HER2 protein, which is found in high amounts on the surface of certain cancer cells (like some breast, stomach, and bile duct cancers). Unlike standard HER2 antibodies such as Herceptin that bind to just one spot, Ziihera binds to two different spots on the HER2 protein simultaneously, which can lead to stronger cancer cell killing and better immune system engagement.
Trial Status
Ziihera is FDA-approved in two indications. The pivotal Phase 3 HERIZON-GEA-01 trial (first-line GEA) met its primary endpoint with statistically significant progression-free and overall survival benefits versus trastuzumab plus chemotherapy, with results published in the New England Journal of Medicine. Final results from the Phase 2 HERIZON-BTC-01 trial (biliary tract cancer) also showed durable responses. A Breakthrough Therapy Designation was granted in August 2026 for HER2-positive colorectal cancer, and Jazz is exploring trials in breast, colorectal, and lung cancers.
The Two-Sided Case
Upcoming Catalysts
- Potential regulatory filing for HER2+ colorectal cancer following August 2026 Breakthrough Therapy Designation (no PDUFA date set)
- Quarterly royalty revenue reports from Jazz/BeOne Ziihera sales
- Jazz Pharmaceuticals' ongoing/planned trials in breast, colorectal, and lung cancers
- Zymeworks' own pipeline progress (ZW209 with Roche, ZW251 GPC3-targeting ADC)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zymeworks Inc. PRESS-RELEASE ZYME ·Originating report